



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/808,878	03/15/2001	James H. Pickar	AM100226	5270

7590

10/01/2002

Egon E. Berg  
American Home Products Corporation  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940

EXAMINER

BAHAR, MOJDEH

ART UNIT

PAPER NUMBER

1617

DATE MAILED: 10/01/2002

10

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/808,878

Applicant(s)

PICKAR, JAMES H.

Examiner

Mojdeh Bahar

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 05 September 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-7, 11, 12 and 15-69 is/are pending in the application.
- 4a) Of the above claim(s) 1-6 and 15-68 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 7, 11, 12 and 69 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 9. 6) ☐ Other: \_\_\_\_\_

**DETAILED ACTION**

***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 5 September 2002 has been entered.

Claims 1-6 and 15-68 drawn to an invention non-elected with traverse in Paper No. 5. Claims 7, 11, 12 and 69 are examined herein in so far as they read on the elected specie of hot flashes.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 7, 11, 12 and 69 are rejected under 35 U.S.C. 103(a) as being unpatentable over Plunkett et al. (USPN RE 36,247).

Plunkett et al. (USPN RE 36,247) teaches a method of treating hot flashes comprising administering continuously and uninterruptedly both progestogen and estrogen in daily dosage units, see claims 21-34, col. 3, lines 51-59 and col.8 lines 62-64 in particular. Plunkett et al. (USPN RE 36,247) also teaches conjugated equine estrogen/medroxyprogesterone as one of the estrogen/progestogen combinations useful in its method, see claims 21-34. Plunkett teaches the

Art Unit: 1617

minimum and maximum dosages for medroxyprogesterone and conjugated equine estrogens to be 1 mg/day and 15 mg/day and 0.300 and 2.5 mg/day (preferred dosage of 0.300-0.600 mg) respectively, see claims 34-35, see also Table 1A, col.4, in particular.

Plunkett et al. does not particularly teach the dosages of conjugated equine estrogen/medroxyprogesterone claimed herein.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to employ conjugated equine estrogen/medroxyprogesterone in the specific dosages claimed herein in a method of treating hot flashes.

One of ordinary skill in the art would have been motivated to employ conjugated equine estrogen/medroxyprogesterone in the specific dosages claimed herein in a method of treating hot flashes because they (dosages herein) fall within the therapeutic ranges of the conjugated equine estrogen/medroxyprogesterone taught by the prior art. Optimization of amounts is within the purview of the Skilled Artisan, and is therefore obvious absent evidence to the contrary. No such evidence is seen.

### ***Response to Arguments***

Applicant's arguments filed September 5, 2002 have been fully considered but they are not persuasive. Applicant first argues that "Plunkett does not describe daily dosage of about 1.5 mg MPA at all." Plunkett teaches that MPA can be employed at a minimum dosage of 1.0 mg and maximum dosage of 15 mg. Note that the claimed dosage herein, 1.5 mg, falls within the Plunkett range. Applicant further argues that the dosage of CEE taught in the prior art is far higher than the amount claimed herein. Note that the claimed dosage herein, 0.3-0.45 mg of CEE, falls within the dosage range of Plunkett, 0.300-0.600 mg, see claim 35 of Plunkett.

Art Unit: 1617

Applicant draws the examiner's attention to data presented in the specification showing the efficacy of the dosages herein versus that of the common daily dosages of Premarin and MPA. Note that in order to overcome obviousness applicant must demonstrate unexpected results in comparison with the closest prior art, i.e., Plunkett. No such comparative data has been provided.

In response to applicant's argument that the examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mojdeh Bahar whose telephone number is (703) 305-1007. The examiner can normally be reached on (703) 305-1007 from Monday to Friday from 9:00 a.m. to 5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (703) 305-1877. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Mojdeh Bahar  
Patent Examiner



SREENI PADMANABHAN  
PRIMARY EXAMINER

9/24/12

Application/Control Number: 09/808,878  
Art Unit: 1617

Page 5

September 16, 2002